Molecular Biology Reports ( IF 2.6 ) Pub Date : 2021-08-30 , DOI: 10.1007/s11033-021-06687-1 Arman Sourani 1 , Saeid Saghaei 1 , Masih Sabouri 1 , Masoud Soleimani 2 , Leila Dehghani 3
|
Abstract
The present systematic review was done to investigate the possible application of Extracellular vesicles (EVs) in the diagnosis, prognosis, and treatment response monitoring of gliomas using available literature to wrap up the final applicable conclusion in this regard. we searched PubMed/MEDLINE, Scopus, and ISI Web of Science databases. Authors evaluated the quality of the included studies by the QUADAS-2 tool. In total, 2037 published datasets were retrieved through systematic search. Upon screening for eligibility, 35 datasets were determined as eligible. Exosome was the EV-subtype described in the majority of studies, and most datasets used serum as the primary EVs isolation source. EVs isolation was primarily conducted by ultracentrifugation. 31 datasets reported that EVs hold considerable potential for being used in diagnostics, with the majority reporting different types of miRNAs as biomarkers. Besides, 8 datasets reported that EVs could be a potential source of prognostic biomarkers. And finally, 3 datasets reported that EVs might be a reliable strategy for monitoring therapy response in glioma patients. According to the findings of the current systematic review, it seems that miR-301, miR-21, and HOTAIR had the highest diagnostic accuracy. However, heterogeneous and limited evidence regarding prognosis and treatment response monitoring precludes us from drawing a practical conclusion regarding EVs.
Graphic abstract
中文翻译：
细胞外囊泡作为非侵入性生物标志物在胶质瘤诊断、预后和治疗反应监测中的系统评价
摘要
本系统评价旨在利用现有文献研究细胞外囊泡 (EV) 在胶质瘤诊断、预后和治疗反应监测中的可能应用，以总结这方面的最终适用结论。我们检索了 PubMed/MEDLINE、Scopus 和 ISI Web of Science 数据库。作者通过 QUADAS-2 工具评估了纳入研究的质量。通过系统搜索总共检索了 2037 个已发布的数据集。在筛选资格后，35 个数据集被确定为合格。外泌体是大多数研究中描述的 EV 亚型，大多数数据集使用血清作为主要的 EV 分离源。EVs 的分离主要是通过超速离心进行的。31 个数据集报告称，电动汽车在诊断方面具有相当大的潜力，大多数报告将不同类型的 miRNA 作为生物标志物。此外，8 个数据集报告称，EV 可能是预后生物标志物的潜在来源。最后，3 个数据集报告说，EV 可能是监测胶质瘤患者治疗反应的可靠策略。根据当前系统评价的结果，似乎 miR-301、miR-21 和 HOTAIR 的诊断准确性最高。然而，关于预后和治疗反应监测的异质和有限的证据使我们无法得出关于 EV 的实际结论。根据当前系统评价的结果，似乎 miR-301、miR-21 和 HOTAIR 的诊断准确性最高。然而，关于预后和治疗反应监测的异质和有限的证据使我们无法得出关于 EV 的实际结论。根据当前系统评价的结果，似乎 miR-301、miR-21 和 HOTAIR 的诊断准确性最高。然而，关于预后和治疗反应监测的异质和有限的证据使我们无法得出关于 EV 的实际结论。
京公网安备 11010802027423号